Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019)
Updates since publication:
No updates on dosing recommendations since publication.
Tables and figure provided in the main manuscript of the guideline:
|Table 1. Assignment of likely CYP2D6 phenotypes based on diplotypes|
|Table 2. Dosing recommendations for atomoxetine based on CYP2D6 genotype for children|
|Table 3. Dosing recommendations for atomoxetine based on CYP2D6 genotype for adults|
|Figure 1. Atomoxetine Pathway, Pharmacokinetics|
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019)
Tables and figures provided in the supplement or referenced in the guidelinea:
|Supplemental Table S1. Evidence linking CYP2D6 to atomoxetine phenotype|
|CYP2D6 allele definition table|
|CYP2D6 allele functionality table|
|CYP2D6 frequency table|
|CYP2D6 diplotype-phenotype table|
Gene Resource Mapping
Drug Resource Mapping
Clinical Decision Support:b
aSome of the tables included in the guideline may have been updated online, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.
This guideline has been endorsed by the American Society for Clinical Pharmacology and Therapeutics.